找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Applied Statistics in Biomedicine and Clinical Trials Design; Selected Papers from Zhen Chen,Aiyi Liu,Yi Tsong Conference proceedings 2015

[復(fù)制鏈接]
樓主: 貶損
31#
發(fā)表于 2025-3-26 21:35:56 | 只看該作者
Bayesian Functional Mixed Models for Survival Responses with Application to Prostate Cancerwhich not only allows dimension reduction of the parameter space but also allows efficient sampling from the conditional distributions. We illustrate our approach with a recent prostate cancer clinical trial study.
32#
發(fā)表于 2025-3-27 05:00:29 | 只看該作者
Bayesian Predictive Approach to Early Termination for Enriched Enrollment Randomized Withdrawal Triabability for observing a sufficient magnitude of response rate at the end of enriched enrollment phase given the observed data at an interim look. The method is applied to derive futility stopping rules, and the sensitivity of the futility stopping rules is examined based upon the choice of prior di
33#
發(fā)表于 2025-3-27 05:55:19 | 只看該作者
Group Sequential Methods for Comparing Correlated Receiver Operating Characteristic Curves and derive the asymptotic covariance structure for comparative ROC statistics. Relating the difference between empirical ROC curves to the Kiefer process, we also show these results can be used to conduct a GSD using standard software.
34#
發(fā)表于 2025-3-27 11:01:18 | 只看該作者
Some Characteristics of the Varying-Stage Adaptive Phase II/III Clinical Trial Designrnative hypotheses for both plausible endpoints. Here, we explore characteristics of the design when the alternative hypothesis for only one of the two endpoints is true, and the treatment effect for another endpoint is null (an extremely worst case) or lower than what was anticipated per trial desi
35#
發(fā)表于 2025-3-27 14:02:36 | 只看該作者
36#
發(fā)表于 2025-3-27 19:30:15 | 只看該作者
37#
發(fā)表于 2025-3-27 23:15:57 | 只看該作者
38#
發(fā)表于 2025-3-28 05:49:34 | 只看該作者
39#
發(fā)表于 2025-3-28 08:53:42 | 只看該作者
Bayesian Design of Noninferiority Clinical Trials with Co-primary Endpoints and Multiple Dose Comparpproach has the potential of power increase and hence sample size reduction due to the incorporation of the historical data and the correlation structure among multiple co-primary endpoints while it still maintains the family-wise type I error control without additional multiplicity adjustment. In t
40#
發(fā)表于 2025-3-28 12:28:54 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 23:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
潼南县| 云梦县| 建宁县| 兴山县| 乃东县| 康定县| 都匀市| 茂名市| 嘉祥县| 芦山县| 临沭县| 长岛县| 平定县| 客服| 凤翔县| 句容市| 广宗县| 镇远县| 额济纳旗| 察哈| 高清| 兖州市| 靖州| 阳谷县| 遂平县| 大城县| 太仓市| 达州市| 武川县| 新巴尔虎左旗| 吴川市| 潼南县| 盐源县| 宜春市| 乌苏市| 淮安市| 忻州市| 张家港市| 芒康县| 甘孜| 乌兰浩特市|